Is treatment of early postmenopausal women with bisphosphonates justified?

International Journal of Clinical Practice

Volumn 61, Issue 6, 2007, Pages 963-971

  Epstein, S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Doylestown Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSTIC PROCEDURE; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; EARLY DIAGNOSIS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTORS; TREATMENT OUTCOME;

EID: 34248369252     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01366.x     Document Type: Review

References (57)

1. Looker AC, Orwoll ES, Johnston CC et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997 12 : 1761 8.
2. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005 16 (Suppl. 2 S3 7.
3. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000 15 : 1965 73.
4. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006 354 : 2250 61.
5. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996 11 : 337 49.
6. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004 19 : 1628 33.
7. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002 288 : 872 81.
8. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004 291 : 1701 12.
9. Lee E, Wutoh AK, Xue Z et al. Osteoporosis management in a Medicaid population after the Women's Health Initiative study. J Womens Health (Larchmt) 2006 15 : 155 61.
10. Pasco JA, Seeman E, Henry MJ et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006 17 : 1404 9.
11. Sanders KM, Nicholson GC, Watts JJ et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006 38 : 694 700.
12. Abrahamsen B, Vestergaard P, Rud B et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2006 21 : 796 800.
13. Siris ES, Brenneman SK, Miller PD et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004 19 : 1215 20.
14. Siris ES, Brenneman SK, Barrett-Connor E et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2006 17 : 565 74.
15. Sornay-Rendu E, Munoz F, Garnero P et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005 20 : 1813 9.
16. Lu Y, Genant HK, Shepherd J et al. Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 2001 16 : 901 10.
17. World Health Organisation. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003 921 : 1 164.
18. Ferrer J, Neyro JL, Estevez A. Identification of risk factors for prevention and early diagnosis of a-symptomatic post-menopausal women. Maturitas 2005 52 (Suppl. 1 S7 22.
19. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005 16 : 229 38.
20. Lydick E, Cook K, Turpin J et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998 4 : 37 48.
21. Cadarette SM, Jaglal SB, Murray TM. Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry. Osteoporos Int 1999 10 : 85 90.
22. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2004 103 : 203 16.
23. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC : National Osteoporosis Foundation, 2003.
24. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 Ed, with selected updates for 2003. Endocr Pract 2003 9 : 544 64.
25. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006 13 : 340 67.
26. Rossini M, Bianchi G, Di Munno O et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006 17 : 914 21.
27. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003 9 : 2643 58.
28. Balena R, Toolan BC, Shea M et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993 92 : 2577 86.
29. Ott SM. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res 1993 8 (Suppl. 2 S597 606.
30. Chesnut CH III., Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 19 : 1241 9.
31. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999 282 : 1344 52.
32. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 280 : 2077 82.
33. Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998 338 : 485 92.
34. McClung MR, Wasnich RD, Hosking DJ et al. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004 89 : 4879 85.
35. Ravn P, Weiss SR, Rodriguez-Portales JA et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000 85 : 1492 7.
36. Eastell R, Barton I, Hannon RA et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003 18 : 1051 6.
37. Hochberg MC, Greenspan S, Wasnich RD et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002 87 : 1586 92.
38. Cranney A, Guyatt G, Griffith L et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002 23 : 570 8.
39. Mortensen L, Charles P, Bekker PJ et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998 83 : 396 402.
40. Hooper MJ, Ebeling PR, Roberts AP et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric 2005 8 : 251 62.
41. McClung MR, Wasnich RD, Recker R et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004 19 : 11 8.
42. Rosenblatt M. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective. J Bone Miner Res 2003 8 : 1142 5.
43. Reginster JY, Abadie E, Delmas P et al. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 2006 17 : 1 7.
44. Watts NB. Is it ethical to use placebos in osteoporosis clinical trials? Curr Osteoporos Rep 2004 2 : 31 6.
45. Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999 42 : 1246 54.
46. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000 85 : 231 6.
47. Bauer DC, Black DM, Garnero P et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004 19 : 1250 8.
48. Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996 11 : 1531 8.
49. Melton LJ III., Khosla S, Atkinson EJ et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997 12 : 1083 91.
50. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006 119 (4 Suppl. 1 S25 31.
51. Ravn P, Hosking D, Thompson D et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999 84 : 2363 8.
52. Harris ST, Gertz BJ, Genant HK et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993 76 : 1399 406.
53. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005 142 : 734 41.
54. Schousboe JT, Bauer DC, Nyman JA et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007 18 : 201 10.
55. Schousboe JT, Ensrud KE, Nyman JA et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int 2005 16 : 1883 93.
56. Schousboe JT, Ensrud KE, Nyman JA et al. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score > -2.5 for alendronate therapy: a modeling study. J Clin Densitom 2006 9 : 133 43.
57. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001 12 : 989 95.